SynthesisStem cell research & therapy2025
Intranasal administration of stem cell derivatives for the treatment of AD animal models: a systematic review and meta-analysis.
Synthesis in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Intranasal natural products for influenza treatment: a systematic review and meta-analysis of preclinical studies.Frontiers in immunology · 2026Pooled it
- Optimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy.Cell transplantationPooled it
- Disease mechanisms and translational barriers guide nanocarrier design for nose to brain delivery in Alzheimer's disease.Discover nano · 2026Review
- Collecting Eggs, Not Killing Chickens: Why Stem Cell Secretome and Exosomes Are Redefining Regenerative Medicine for Healthspan Extension.Biomedicines · 2026Review
- Transplantation immunology: paradigm shift from systemic suppression to microenvironment remodeling and precision modulation.Frontiers in cell and developmental biology · 2026Review
- Transcriptomic analysis reveals that BVDV alters immune and metabolic responses toFrontiers in veterinary science · 2026Article
- Research on the Application of Mesenchymal Stem Cells for Addressing Mitochondrial Damage in Neurodegenerative Diseases.Cellular and molecular neurobiology · 2025Review
- Cell Membrane- and Vesicle-Based Bionic Nanodrugs: Applications in Central Nervous System Diseases and Exploration of Nasal-Cerebral Delivery.Gels (Basel, Switzerland) · 2025Review
- Intranasal adipose-derived stem cells mitigate cuprizone-induced demyelination in mouse corpus callosum by modulating oligodendrocyte and microglial marker expression: histological and ultrastructural insights.Journal of molecular histology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAlzheimer’s disease (AD) is a neurodegenerative disorder with increasing prevalence and limited efficacy of current therapies. Stem cell-derived therapies have attracted attention for their potential neurodegenerative and reparative effects. Intranasal administration provides a non-invasive route that bypasses the blood-brain barrier and delivers stem cell derivatives directly to the brain. Although studies have shown that the intranasal administration of stem cell derivatives alleviates symptoms in animal models of AD, a comprehensive meta-analysis evaluating their therapeutic efficacy is yet to be conducted. This study aims to evaluate the efficacy of intranasal stem cell derivatives therapies in AD animal models and provide a foundation for clinical translation.
methodsWe conducted a systematic literature search across four databases (Pubmed, Embase, Web of Science and Cochrane Library) using subject terms and complementary keywords. After applying inclusion and exclusion criteria, data were extracted using Origin 2024 software and analysed using Review Mange 5.4. The SYRCLE tool was applied to assess study quality and evaluate the potential risk of bias systematically.
resultsThis meta-analysis of 14 studies investigated the efficacy of intranasal stem cell-derived therapies in animal models of Alzheimer’s disease (AD). Using predominantly mouse and rat models from diverse geographical locations and employing various stem cell types (bone marrow, umbilical cord blood, adipose tissue, hiPSCs), the analysis revealed a significant reduction in amyloid-beta (Aβ) deposition (SMD = -2.69, p < 0.0001). Subgroup analyses indicated that stem cell source, stem cell derivative types and Aβ detection method were not primary drivers of heterogeneity. Furthermore, treatment significantly reduced inflammatory markers IL-1β (SMD = -0.92, p = 0.008) and IBA-1 (SMD = -1.68, p = 0.006), suggesting an anti-inflammatory effect. Auxiliary outcomes CD68 and GFAP also exhibited decreased expression levels. Improved cognitive function was evident, as measured by increased target quadrant dwell time (MD = 10.17, p < 0.00001) and decreased escape latency (MD = -15.74, p = 0.003) in behavioral experiments, and enhanced recognition in the Novel Object Recognition Test (NORT) (SMD = 1.10, p = 0.006). Nissl staining demonstrated a significant reduction in neuronal cell death (SMD=-3.33,p < 0.00001),suggesting a role in neuronal repair.Together, these findings support the potential of intranasal stem cell-derived therapies to improve Alzheimer’s disease pathology, neuronal repair, and cognition in animal models.
conclusionIntranasal administration of stem cell derivatives has demonstrated efficacy in Alzheimer’s disease (AD) animal models, leading to reductions in amyloid-beta (Aβ) deposition, cognitive improvement, repair neurons and attenuation of inflammatory responses. However, limitations such as potential publication bias and heterogeneity among existing studies are noted. Due to insufficient data and study limitations, additional preclinical and clinical trials are required to confirm these results and explore the therapy’s long-term safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.